{"id":"NCT00541775","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Safety/Efficacy of Sitagliptin in Patient w/ Type 2 Diabetes (0431-801)","officialTitle":"A Multicenter, Double-Blind, Placebo and Active Controlled, Randomized Study to Evaluate the Safety and Efficacy of the Addition of Sitagliptin 100 mg Once Daily in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin Monotherapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-06","primaryCompletion":"2007-03","completion":"2007-03","firstPosted":"2007-10-10","resultsPosted":"2010-06-17","lastUpdate":"2015-08-24"},"enrollment":273,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"Sitagliptin","otherNames":["Januvia"]},{"type":"DRUG","name":"Comparator: Rosiglitazone","otherNames":["Avandia"]},{"type":"DRUG","name":"Comparator: Placebo","otherNames":[]},{"type":"DRUG","name":"Comparator: Metformin","otherNames":[]}],"arms":[{"label":"Sitagliptin","type":"EXPERIMENTAL"},{"label":"Rosiglitazone","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to test the safety and effectiveness of sitagliptin in patients with type 2 diabetes.","primaryOutcome":{"measure":"Hemoglobin A1C (A1C) at Week 18","timeFrame":"Baseline and 18 Weeks","effectByArm":[{"arm":"Sitagliptin","deltaMin":-0.73,"sd":null},{"arm":"Rosiglitazone","deltaMin":-0.79,"sd":null},{"arm":"Placebo","deltaMin":-0.22,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":"<=0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":3,"exclusionCount":5},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["18201203"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":94},"commonTop":["Blood glucose increased"]}}